original ) (raw )Finckh A. Joint damage progression in patients with rheumatoid arthritis in clinical remission. Do biologics perform better than synthetic antirheumatic drugs
Axel Finckh
2016
View PDFchevron_right
No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal comparative MRI, ultrasonography, CT and radiography study
Merete Hetland
Annals of the Rheumatic Diseases, 2011
View PDFchevron_right
Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosion
C. Stach
Annals of the Rheumatic Diseases, 2011
View PDFchevron_right
May Etanercept and PTH (1-34) association heal erosions in early rheumatoid arthritis? A pilot study
A. Migliore , Giuseppe Argento
European review for medical and pharmacological sciences
View PDFchevron_right
Evaluation of IL1-� and Tnf� Serum Levels in Rheumatoid Arthritis Pationts with Active and Inactive, with or Without Bone Erosion
Abdolrahman Rostamian
2007
View PDFchevron_right
Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists
Axel Finckh
Annals of the Rheumatic Diseases, 2012
View PDFchevron_right
Infliximab in the treatment of rheumatoid arthritis
Aleth Perdriger
Aging Health, 2006
View PDFchevron_right
Infliximab treatment of rheumatoid arthritis
Ravinder Maini
Rheumatic Disease Clinics of North America, 2004
View PDFchevron_right
Erosion-free rheumatoid arthritis: clinical and conceptional implications—a BARFOT study
Kristina Forslind
BMC rheumatology, 2022
View PDFchevron_right
Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis
Ted Mikuls
Current rheumatology reports, 2003
View PDFchevron_right
Effect of treat-to-target strategies on bone erosion progression in early rheumatoid arthritis: An HR-pQCT study
jiang yue
Seminars in arthritis and rheumatism, 2018
View PDFchevron_right
Repair of Local Bone Erosions and Reversal of Systemic Bone Loss Upon Therapy with Anti-Tumor Necrosis Factor in Combination with Osteoprotegerin or Parathyroid Hormone in Tumor Necrosis Factor-Mediated Arthritis
Helga Bergmeister
The American Journal of Pathology, 2004
View PDFchevron_right
Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission?
Ravinder Maini
Arthritis & Rheumatism, 2002
View PDFchevron_right
Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J)
Yoshiya Tanaka
Modern Rheumatology, 2008
View PDFchevron_right
A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab
Hubert Marotte
Arthritis Research & Therapy, 2007
View PDFchevron_right
Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up
Ahmed Fathy
International Journal of Rheumatic Diseases, 2012
View PDFchevron_right
Healing of erosions in rheumatoid arthritis
Pekka Hannonen
Annals of the Rheumatic Diseases, 2000
View PDFchevron_right
Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase...
Yoshiya Tanaka
Annals of the rheumatic diseases, 2015
View PDFchevron_right
Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis
Barbara Segal
Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology, 2008
View PDFchevron_right
Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate
Paul Tak
Annals of the Rheumatic Diseases, 2010
View PDFchevron_right
Serum IgA rheumatoid factor and pyridinoline in very early arthritis as predictors of erosion(s) at two years: A simple model of prediction from a conservatively treated community-based inception cohort
Patrice Fardellone , Michel Brazier , Othmane Mejjad
Arthritis Care & Research, 2010
View PDFchevron_right
Radiographic data from recent randomized controlled trials in rheumatoid arthritis: What have we learned?
vibeke strand
Arthritis & Rheumatism, 2003
View PDFchevron_right
Trajectory of radiographic change over a decade: the effect of transition from conventional synthetic disease-modifying antirheumatic drugs to anti-tumour necrosis factor in patients with psoriatic arthritis
Charlotte Cavill
Rheumatology, 2018
View PDFchevron_right
Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study
Juergen Rech
Annals of the Rheumatic Diseases, 2013
View PDFchevron_right
Evidence from clinical trials and long���term observational studies that disease���modifying anti���rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review
Irving Kushner
2002
View PDFchevron_right
Intima-media thickness evolution after treatment with infliximab in patients with rheumatoid arthritis
Lidia Rota
International Journal of General Medicine, 2009
View PDFchevron_right
Rheumatoid Arthritis: Refractory to Infliximab, a Tumor Necrosis Factor Inhibitor
S. Sazliyana , Sakthiswary Rajalingham
Journal of Clinical Medicine Research, 2011
View PDFchevron_right
Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: Effects on synovial inflammation, bone erosion, and cartilage destruction
Helga Bergmeister
Arthritis & Rheumatism, 2004
View PDFchevron_right
Dose reduction of TNF blockers in rheumatoid arthritis: clinical and pharmacological aspects
A. van der Maas
2013
View PDFchevron_right
Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: Five-year experience from the FIN-RACo study
Leena Laasonen
Arthritis & Rheumatism, 2004
View PDFchevron_right